AVI BioPharma 2007 News Archive

December

AVI BioPharma Announces Commencement of Dosing in Clinical Trial for Duchenne Muscular Dystrophy December 21, 2007, PORTLAND, Ore.
AVI BioPharma, Inc. Completes Registered Direct Offering, Raises $20.3 Million December 19, 2007, PORTLAND, Ore.
AVI BioPharma, Inc. to Raise $20.3 Million in Registered Direct Offering December 13, 2007, PORTLAND, Ore.
AVI BioPharma Receives Fast Track Designation for AVI–4658 for Treatment of Duchenne Muscular Dystrophy December 3, 2007, PORTLAND, Ore.

November

AVI BioPharma Incorporated Third Quarter 2007 Results Conference Call Transcript November 16, 2007, PORTLAND, Ore.
AVI BioPharma to Present on NeuGene Countermeasures to Biological Threats at U.S. Department of Defense 2007 Biodefense Research Conference November 6, 2007, PORTLAND, Ore.
AVI BioPharma Announces Third Quarter Financial Results November 6, 2007, PORTLAND, Ore.
AVI BioPharma President and COO to Speak at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference November 5, 2007, PORTLAND, Ore.
AVI BioPharma Receives Orphan Drug Designation for AVI–4658 for Treatment of Duchenne Muscular Dystrophy November 1, 2007, PORTLAND, Ore.

October

AVI BioPharma Announces 2007 Third Quarter Financial Results Conference Call October 30, 2007, PORTLAND, Ore.
AVI BioPharma Announces Changes to Its Board of Directors October 30, 2007, PORTLAND, Ore.
AVI BioPharma Provides Update on Clinical Trial for Treatment of Duchenne Muscular Dystrophy October 26, 2007, PORTLAND, Ore.
AVI BioPharma Announces Partner Breakfast Symposium at 2007 Transcatheter Cardiovascular Therapeutics Conference October 25, 2007, PORTLAND, Ore.
AVI BioPharma Announces Intention to Restate Financial Statements October 24, 2007, PORTLAND, Ore.
AVI BioPharma Receives Major Research and Development Grant From Charley’s Fund for Duchenne Muscular Dystrophy October 15, 2007, PORTLAND, Ore. and SOUTH EGREMONT, Mass.

September

AVI BioPharma Receives Department of Defense Contract for NeuGene Program in Dengue Virus September 19, 2007, PORTLAND, Ore.
AVI BioPharma Drug Demonstrates Strong Survival Benefits and Elimination of Ebola Virus in Animals September 12, 2007, PORTLAND, Ore.

August

AVI BioPharma Incorporated Second Quarter 2007 Results Conference Call Transcript August 13, 2007, PORTLAND, Ore.
AVI BioPharma Announces Second Quarter Financial Results August 8, 2007, PORTLAND, Ore.
AVI BioPharma Announces Refocused Clinical Development Strategy August 8, 2007, PORTLAND, Ore.
AVI BioPharma Announces 2007 Second Quarter Financial Results Conference Call August 1, 2007, PORTLAND, Ore.

July

AVI BioPharma Partner Global Therapeutics Announces Positive Pre–Clinical Results Shown Using NeuGene Antisense Drug in Prevention of Cardiovascular Restenosis July 25, 2007, PORTLAND, Ore.
AVI BioPharma Announces Positive Pre–Clinical Study Results Presented at the 26th Annual Meeting of the American Society for Virology July 17, 2007, PORTLAND, Ore.
AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease July 10, 2007, PORTLAND, Ore.
APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease Announces Completion of Patient Enrollment July 9, 2007, BLOOMINGTON, Ind.

May

AVI BioPharma Incorporated First Quarter 2007 Financial Results Conference Call Transcript May 11, 2007, PORTLAND, Ore.
AVI BioPharma Announces First Quarter Financial Results May 9, 2007, PORTLAND, Ore.
AVI BioPharma Receives DoD Contracts for Bioterrorism Response Therapies May 7, 2007, PORTLAND, Ore.
AVI BioPharma and Ercole Biotech Announce License and Drug Development Agreement for Duchenne Muscular Dystrophy and Beta Thalassemia May 2, 2007, PORTLAND, Ore.
AVI BioPharma Announces 2007 First Quarter Financial Results Conference Call May 2, 2007, PORTLAND, Ore.
AVI BioPharma Reports Positive Pre–Clinical Influenza Data May 1, 2007, PORTLAND, Ore.

April

AVI BioPharma Completes Purchase of Building for GMP Manufacturing April 20, 2007, PORTLAND, Ore.

March

AVI BioPharma Chairman and CEO Resigns March 28, 2007, PORTLAND, Ore.
AVI BioPharma Incorporated 2006 Fourth Quarter Financial Results Conference Call Transcript March 23, 2007, PORTLAND, Ore.
AVI BioPharma Announces 2006 Fourth Quarter and Full Year Financial Results March 15, 2007, PORTLAND, Ore.
AVI BioPharma to Present Business Strategy at Cowen and Company’s 27th Annual Health Care Conference March 13, 2007, PORTLAND, Ore.
AVI BioPharma Announces 2006 Fourth Quarter and Year End Financial Results Conference Call March 8, 2007, PORTLAND, Ore.
AVI BioPharma Presents Novel HIV Drug Candidate Results March 1, 2007, PORTLAND, Ore.

January

AVI BioPharma and Eleos Announce Cross–License Agreement for p53 Therapeutics January 9, 2007, PORTLAND, Ore., and OMAHA, Neb.

About AVI BioPharma

Technology

Communication